# US 8,278,067 B2 · Method for inhibiting hyperpigmentation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,067 B2
- Document ID: US8278067B2
- Status: Granted
- Kind: B2
- Application number: 13/048,622
- Filed: 2011-03-15
- Published: 2012-05-10
- Granted: 2012-10-02
- Earliest claimed: 1999-05-06
- Assignees: The Trustees of Columbia University in the City of New York
- Inventors: B. Jack Longley
- Web page: https://patentgrep.com/patent/US8278067B2

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treating contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.

## Claims

### Claim 1

A method of preventing or treating in a subject hyperpigmentation which comprises administering to the subject an amount of a compound which inhibits, the stem cell factor signaling pathway effective to prevent or treat hyperpigmentation so as to thereby prevent or treat hyperpigmentation in the subject wherein the compound inhibits a kinase enzymatic reaction of kit protein of the stem cell factor signaling pathway.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound inhibits chymase, elastase or other SCF cleaving enzymes of the stem cell factor signaling pathway.

### Claim 3 (depends on 1)

The method of claim 1, wherein inhibiting the stem cell factor signaling pathway comprises inhibiting kit dimerization with a compound which is an antibody, peptide, or nonpeptide chemical.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound inhibits downstream signaling of the kit activation pathway by blocking substrate association with kit kinase domain.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound inhibits downstream signaling of the kit activation pathway by blocking enzymatic function in the downstream signaling pathway.

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound is an anti-kit antibody or portion thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the compound is a monoclonal antibody.

### Claim 8 (depends on 7)

The method of claim 7, wherein the monoclonal antibody is a human, humanized or a chimeric antibody.

### Claim 9

The method of claim, wherein the anti-kit antibody is ACK2.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound comprises a Fab fragment of an anti-kit antibody.

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound comprises a variable domain of an anti-kit antibody.

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound comprises one or more CDR portions of an anti-kit antibody.

### Claim 13 (depends on 12)

The method of claim 12, wherein the antibody is selected from the group consisting of IgA, IgD, IgE, IgG and IgM.

### Claim 14 (depends on 1)

The method of claim 1, wherein the compound comprises a peptide, peptidomimetic, a nucleic acid, or an organic compound with a molecular weight less than 500 Daltons.

### Claim 15 (depends on 1)

The method of claim 1, wherein the compound is sSCF, sKIT ligand or a fragment thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the compound is SKIT or a fragment thereof.

### Claim 17 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 18 (depends on 17)

The method of claim 17, wherein the mammal is a human being, dog or cat.

### Claim 19 (depends on 1)

The method of claim 1, wherein the administration is intralesional, intraperitoneal, intramuscular, subcutaneous, intravenous, liposome mediated delivery, transmucosal, intestinal, topical, nasal, oral, anal, ocular, otic, intravesicular, or parenteral.
